U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H23N5O2S.CH4O3S
Molecular Weight 553.653
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Ro-31-8220 mesylate

SMILES

CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C3=C(C(=O)NC3=O)C4=CN(CCCSC(N)=N)C5=CC=CC=C45

InChI

InChIKey=SAWVGDJBSPLRRB-UHFFFAOYSA-N
InChI=1S/C25H23N5O2S.CH4O3S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20;1-5(2,3)4/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula C25H23N5O2S
Molecular Weight 457.547
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21943284 | https://www.ncbi.nlm.nih.gov/pubmed/10998351 | https://www.ncbi.nlm.nih.gov/pubmed/16302800 |

RO-31-8220 is a cell-permeable staurosporine analog, that shows potent inhibition of PKC α, PKC βI, PKC βII, PKC γ, and PKC ε. Ro 31-8220 also inhibits MSK1, MAPKAPK1, RSK, GSK3β, and S6K1 with a potency similar to that for PKC. Ro 31-8220 alters cellular protein kinase C localization and potently inhibits the growth of A549 and MCF-7 cells with IC50 of 0.78 μM and 0.897 μM, respectively. RO 31-8220 enhances epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. Ro 31-8220 significantly decreases apoE secretion from primary human macrophages by inhibiting vesicular transport of apoE to the plasma membrane without significantly affecting apoE mRNA or apoE protein levels.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey.
1997 Jan
Protein phosphatase-protein kinase interplay modulates alpha 1b-adrenoceptor phosphorylation: effects of okadaic acid.
2000 Feb
ERK signaling mediates the induction of inflammatory cytokines by bufalin in human monocytic cells.
2000 Mar
Regulation of SP-B and SP-C secretion in rat type II cells in primary culture.
2001 Dec
Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species.
2001 Jun
Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions.
2001 Nov 9
Gene expression profile in BALB/c-3T3 cells transformed with beryllium sulfate.
2001 Sep
Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway.
2002 Jan
Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929.
2002 Jul 15
Regulation of cyclooxygenase-2 expression by phospholipase D in human amnion-derived WISH cells.
2002 Mar
Up-regulation of c-jun mRNA in cardiac myocytes requires the extracellular signal-regulated kinase cascade, but c-Jun N-terminal kinases are required for efficient up-regulation of c-Jun protein.
2002 Nov 15
Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A2A adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells.
2003 Apr 25
Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells.
2003 Mar 15
Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process.
2003 Nov 14
Arsenite stimulated glucose transport in 3T3-L1 adipocytes involves both Glut4 translocation and p38 MAPK activity.
2003 Oct
Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin.
2004 Feb 1
Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages.
2004 Sep
Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
2005 Aug
Roles of protein kinase C, Ca2+, Pyk2, and c-Src in agonist activation of rat lacrimal gland p42/p44 MAPK.
2006 Aug
P2Y12 receptor signalling towards PKB proceeds through IGF-I receptor cross-talk and requires activation of Src, Pyk2 and Rap1.
2006 Aug
Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells.
2006 Feb
Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species.
2006 Jul 1
Zinc is required for Fc epsilon RI-mediated mast cell activation.
2006 Jul 15
Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells.
2006 Sep 15
A genomic screen for activators of the antioxidant response element.
2007 Mar 20
Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling.
2009 Nov 15
All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta.
2011 Aug
Molecular investigation of the effects of lindane in rat hepatocytes: microarray and mechanistic studies.
2011 Dec
SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration.
2011 May 26
MAPK- and PKC/CREB-dependent induction of interleukin-11 by the environmental contaminant formaldehyde in human bronchial epithelial cells.
2012 Feb 6
Novel Nrf2/ARE activator, trans-Coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathway.
2015 Sep 21
Patents

Patents

Sample Use Guides

MLP−/− Mice were treated with Ro 31-8220 at dose 6 mg/kg/d, s.c.
Route of Administration: Other
To compare the effect of PKC inhibition or downregulation on neuritogenesis, at 24 h after plating, the neuroblastoma x •glioma NG108-15 hybrid cells were placed in serum free high-glucose DMEM supplemented with 0.015% dimethyl sulfoxide (DMSO) (control) or 1 mkm Go6983 plus 1 mkm Ro318220 to inhibit PKCs or with 300 nm PMA to downregulate PKCs, and morphological changes were examined after 24 or 48 h.
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:54:07 UTC 2023
Edited
by admin
on Sat Dec 16 19:54:07 UTC 2023
Record UNII
3JPC9J3C82
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Ro-31-8220 mesylate
Code English
Methanesulfonic acid 3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate
Systematic Name English
Ro-31-8220 methanesulfonate
Common Name English
Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester, methanesulfonate (1:1)
Systematic Name English
Ro 31-8220 mesylate
Common Name English
Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester, monomethanesulfonate
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID00896763
Created by admin on Sat Dec 16 19:54:07 UTC 2023 , Edited by admin on Sat Dec 16 19:54:07 UTC 2023
PRIMARY
PUBCHEM
11628205
Created by admin on Sat Dec 16 19:54:07 UTC 2023 , Edited by admin on Sat Dec 16 19:54:07 UTC 2023
PRIMARY
CAS
138489-18-6
Created by admin on Sat Dec 16 19:54:07 UTC 2023 , Edited by admin on Sat Dec 16 19:54:07 UTC 2023
PRIMARY
FDA UNII
3JPC9J3C82
Created by admin on Sat Dec 16 19:54:07 UTC 2023 , Edited by admin on Sat Dec 16 19:54:07 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
PARENT -> SALT/SOLVATE